| Literature DB >> 19497068 |
Verena Freiberger1, Kerstin Amann, Uwe Heemann, Helga Frank.
Abstract
Recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation with nephrotic syndrome is a serious problem with a high risk of graft loss. The therapeutic role of renin-angiotensin-system (RAS) blockers in recurrent FSGS is not clear. We present the safety and efficacy of an intensified triple RAS blockade with an ACE-inhibitor, an AT 1 receptor blocker and the direct renin inhibitor aliskiren in a 29-year-old renal transplant recipient with biopsy proven recurrence of FSGS and relapsing severe nephrotic syndrome. We subsequently used full dose ramipril, candesartan and aliskiren under a close monitoring of kidney function and electrolytes and examined the effect on proteinuria, clinical course and tolerability over 12 months. We found a significant and sustained antiproteinuric effect under triple RAS blockade. RAS blockade was generally well tolerated. This can offer a new therapeutic approach in selected hypertensive patients with recurrent FSGS.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19497068 DOI: 10.1111/j.1432-2277.2009.00897.x
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.782